Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

Wells Fargo said the U.S. Supreme Court’s decision to preserve no-cost coverage for preventive services marks a “win for Gilead” and its upcoming launch of lenacapavir (Yeztugo), the company’s ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

The US Food and Drug Administration (FDA) approved Yeztugo, a long-awaited semi-annual injectable treatment for the prevention of HIV, developed by Gilead Sciences. The approval of Yeztugo marks a ...

Tamar Braxton has announced a new brand partnership with Gilead Sciences. The music veteran will help educate and raise ...